CN105614886A - Health food for treating rheumatism - Google Patents
Health food for treating rheumatism Download PDFInfo
- Publication number
- CN105614886A CN105614886A CN201610036925.0A CN201610036925A CN105614886A CN 105614886 A CN105614886 A CN 105614886A CN 201610036925 A CN201610036925 A CN 201610036925A CN 105614886 A CN105614886 A CN 105614886A
- Authority
- CN
- China
- Prior art keywords
- fst
- health food
- polypeptide
- prt
- artificial sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013402 health food Nutrition 0.000 title claims abstract description 79
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 86
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 81
- 229920001184 polypeptide Polymers 0.000 claims abstract description 77
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 6
- 229930006000 Sucrose Natural products 0.000 claims abstract description 6
- 239000005720 sucrose Substances 0.000 claims abstract description 6
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 5
- 229920002472 Starch Polymers 0.000 claims abstract description 5
- 239000008107 starch Substances 0.000 claims abstract description 5
- 235000019698 starch Nutrition 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 10
- 241000628997 Flos Species 0.000 claims description 4
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 4
- 241000180649 Panax notoginseng Species 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 14
- 235000013305 food Nutrition 0.000 abstract description 7
- 239000002994 raw material Substances 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 2
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 240000009088 Fragaria x ananassa Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract 1
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 1
- 240000000038 Ziziphus mauritiana Species 0.000 abstract 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 abstract 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 abstract 1
- 235000008434 ginseng Nutrition 0.000 abstract 1
- 235000021012 strawberries Nutrition 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 201000003068 rheumatic fever Diseases 0.000 description 3
- 241001251068 Formica fusca Species 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010070918 Bone deformity Diseases 0.000 description 1
- 206010051728 Bone erosion Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention provides a health food and belongs to the technical field of health foods. The food is characterized by being prepared from the following raw materials in parts by weight: 35g of herba epimedii, 17g of radix achyranthis bidentatae, 25g of ginseng, 7g of pseudo-ginseng, 50g of carthamus tinctorius, 10g of goldhair grmnopteris herb or rhizome, 10g of yellow mushrooms, 0.1g of polypeptide, 20g of dried Chinese dates, 20g of dried strawberries, 5g of sucrose and 100g of starch. The product provided by the invention has the remarkable effect of treating rheumatism and has very great helps for alleviating rheumatism of human bodies; and the product is low in production cost, easy to produce and low in cost.
Description
Technical field
The invention belongs to technical field of health care food, be specifically related to a kind of health food with treatment rheumatism function.
Background technology
Rheumatism is clinical common a kind of to be changed to main systemic disease with joint. Along with the raising of people's living standard, such disease presents the trend that sickness rate improves year by year in general population. Rheumatoid arthritis (RA) is a kind of common autoimmune disease, is characterized in arthroncus, and deformation finally destruction health are to handicap. Rheumatism includes the disease of muscle, tendon, joint, skeleton or muscle, and it is generally of inflammation and/or degeneration feature. The people of about 1% to 2% suffers from rheumatoid arthritis, and its feature is the pro-inflammatory cytokine that immune system disorder causes overproduction, such as TNF-a, IL-1 and shortage anti-inflammatory cytokines, for instance IL-10, IL-1. The feature of rheumatoid arthritis is synovial membrane inflammation, is developed to cartilage destruction, bone erosion and deformity of joint subsequently. In inflammatory process, neutrophilic granulocyte, macrophage and lymphocyte are released. Activated T-lymphocytes produces cytotoxin and pro-inflammatory cytokine, and macrophage irritates prostaglandin and cytotoxic release simultaneously. Vaso-active substance is in the edema that inflammatory sites discharges and the joint that causes inflammation is relevant, intensification, erythema and pain.
In state-owned nearly ten million population suffering rheumatic arthritis, women is that male is more than 3 times. Modal morbidity is at 40 years old to 50 years old, but the people at any age can also be affected. It brings great misery to patient, even partial paralysis, and causes that basic operational function is lost in tissue deformation. Up to the present, but without known Drug therapy or elimination rheumatoid arthritis. The therapeutic choice of current rheumatoid arthritis has potential toxic and side effects and limitation. Known use glucocorticoid and non-steroidal anti-inflammatory drug (NSAIDs) treat rheumatoid arthritis for some time, and this is considered the expectant treatment of rheumatoid arthritis. Steroid, the cortisone hormone sensitive lipase gene thing of human body self, it is used to suppress the development of rheumatoid arthritis. They can effectively reduce inflammation and suppress autoimmune. The most frequently used steroid hormone is prednisone and dexamethasone. But life-time service dexamethasone can produce side effect, as body weight increases, face becomes round, and skin and bone are thinning, and powder delivery is perverse, easy bruise, hypertension, and increases diabetes, the risk infecting and having a stomachache. Therefore, they only short-period used when acute attack.
It is therefore desirable to have a kind of low cost, safety, rheumatism for the treatment of or alleviate that is effective and less or that be free from side effects brings the health product, particularly health food of harm to the mankind, in order to can life-time service.
Summary of the invention
In order to make up the deficiencies in the prior art, the invention provides and a kind of make health food of sharp rheumatism simple, that cost is low, to have prevention good with therapeutic effect and preparation method thereof.
The technical solution used in the present invention is:
A kind of health food, it is characterised in that being made up of following component: Herba Epimedii 35g, Radix Achyranthis Bidentatae 17g, people 25g, Radix Notoginseng 7g, Flos Carthami 50g, Radix seu Herba Gymnopteris vestitae 10g, yellow mushroom 10g, polypeptide 0.1g, dry Fructus Jujubae 20g, Fructus Fragariae Ananssae does 20g, sucrose 5g, starch 100g.
The present invention additionally provides the preparation method of a peptide species, it is dissolved in acetone after Formica fusca is washed homogenate defat, centrifugal residue obtained water is made into suspension, suspension is heated 10 minutes-15 minutes at 85 �� of C-95 �� of c, adjust pH value to 7.5-8.5 after cooling, add pepsin and trypsin hydrolyzing 1.5h, adjust pH value to 4-5 after sterilizing, centrifugal or filtration gained supernatant is polypeptide solution, described polypeptide solution glucosan G-50 (SephadexG-50) (1.5cm �� 90cm) is separated, 20mmol/LHCl eluant solution, flow velocity 1.3mL/ minute, collect the eluted product of different time periods respectively, by checking order, there are the sequence of 96 little peptides. through checking, 57 little peptides are wherein had to have the function promoting rheumatism therapy. according to the peak separation time different in chromatographic column, it is possible to batch obtains corresponding little peptide. through vacuum concentration and lyophilization, obtain pure polypeptide product. wherein 57 polypeptide are respectively designated as FST-1, FST-2, FST-4, FST-7, FST-8, FST-9, FST-11, FST-13, FST-16, FST-19, FST-20, FST-22, FST-23, FST-25, FST-27, FST-29, FST-32, FST-33, FST-35, FST-37, FST-38, FST-39, FST-42, FST-44, FST-46, FST-48, FST-49, FST-50, FST-52, FST-54, FST-55, FST-57, FST-59, FST-62, FST-64, FST-65, FST-66, FST-67, FST-68, FST-69, FST-70, FST-72, FST-74, FST-75, FST-77, FST-79, FST-81, FST-82, FST-83, FST-85, FST-86, FST-88, FST-90, FST-92, FST-93, FST-94, FST-96. its aminoacid sequence is respectively as shown in SEQIDNO:1-57 order. wherein the scale application of polypeptide can pass through synthetic batch acquisition.
A kind of preparation method treating rheumatism health food, comprises the following steps:
I) take Herba Epimedii 35g, Radix Achyranthis Bidentatae 17g, people 25g, Radix Notoginseng 7g, Flos Carthami 50g, Radix seu Herba Gymnopteris vestitae 10g, yellow mushroom 10g mixing, pulverize, add 1000ml water, decoct and be reduced to the 1/4 of addition to moisture, filter to obtain medicinal liquid, cooling, dry and obtain pressed powder;
2) by polypeptide 0.1g, dry Fructus Jujubae 20g, Fructus Fragariae Ananssae does 20g, sucrose 5g, the pressed powder mixing of starch 100g and the 1 step, packaging after sterilized.
The invention have the benefit that
Present invention process is simple, and raw material is cheap and easy to get, and cost is low; By the compatibility of each component and reasonable dosage so that the health food of the treatment rheumatism of the present invention is suitable for eating, having prevention and treat rheumatismal effect. Although there being Chinese medicine ingredients, but Fructus Fragariae Ananssae is dry, the taste of Fructus Jujubae and sucrose can cover Chinese medicine bitterness, suitable edible.
Detailed description of the invention
The preparation of embodiment 1 polypeptide
It is dissolved in acetone after Formica fusca is washed homogenate defat, centrifugal residue obtained water is made into suspension, suspension is heated 10 minutes-15 minutes at 85 �� of C-95 �� of c, adjust pH value to 7.5-8.5 after cooling, add pepsin and trypsin hydrolyzing 1.5h, adjust pH value to 4-5 after sterilizing, centrifugal or filtration gained supernatant is polypeptide solution, described polypeptide solution glucosan G-50 (SephadexG-50) (1.5cm �� 90cm) is separated, 20mmol/LHCl eluant solution, flow velocity 1.3mL/ minute, collect the eluted product of different time periods respectively, by checking order, there are the sequence of 96 little peptides. through checking, 57 little peptides are wherein had to have the function promoting rheumatism therapy. according to the peak separation time different in chromatographic column, it is possible to batch obtains corresponding little peptide. through vacuum concentration and lyophilization, obtain pure polypeptide product.
The preparation of embodiment 2 health food
I) take Herba Epimedii 35g, Radix Achyranthis Bidentatae 17g, people 25g, Radix Notoginseng 7g, Flos Carthami 50g, Radix seu Herba Gymnopteris vestitae 10g, yellow mushroom 10g mixing, pulverize, add 1000ml water, decoct and be reduced to the 1/4 of addition to moisture, filter to obtain medicinal liquid, cooling, dry and obtain pressed powder;
2) by polypeptide 0.1g, dry Fructus Jujubae 20g, Fructus Fragariae Ananssae does 20g, sucrose 5g, the pressed powder mixing of starch 100g and the 1 step, packaging after sterilized.
Wherein polypeptide is respectively adopted the one of SEQIDNO:1-57 and prepares together with other component and become a kind of health food, prepares 57 different food altogether, wherein adopts the health food that other component being not added with polypeptide prepares as comparison.
Embodiment 3 functional verification
Choose the outpatient suffering from rheumatoid arthritis, according to Americanism damp disease association sorting criterion, want case history 116 example of the patient's condition, male 58 examples, female 58 example without other. Its age in 28-60 year, average 43.6 years old; Course of disease 0.8-12, is found by health check-up, and the rheumatoid factor of all patients, erythrocyte sedimentation rate, blood uric acid index all exceed standard. These patients all accepted the treatment of other resisting rheumatoid disease medicines various in the past, and curative effect is bad or Relapse rate.
Therapeutic Method
All cases is randomly divided into resisting rheumatoid disease health food treatment group 57 groups (often 2 patients of group) 10g food every day and matched group 1 group (2 patients, respectively edible methotrexate (7.5mg/ time, take once weekly)), and normal person is as negative control. Detection safety in every two weeks and adaptability, and carried out comprehensive curative effect evaluation at the 10th week. By blood test, obtain result as follows:
| Rheumatoid factor (iu/ml) | Erythrocyte sedimentation rate (mm/h) | Blood uric acid (��m ol/l) | |
| Negative control | 10.5 | 14.2 | 179.5 |
| Matched group (before taking medicine) | 20.5 | 49.2 | 580.7 |
| Matched group (after taking medicine) | 16.8 | 23.9 | 455.2 |
| The health food that FST-1 polypeptide is corresponding | 10.8 | 15.2 | 188.7 |
| The health food that FST-2 polypeptide is corresponding | 10.7 | 14.8 | 187.6 |
| The health food that FST-4 polypeptide is corresponding | 10.6 | 14.9 | 186.5 |
| The health food that FST-7 polypeptide is corresponding | 10.9 | 15.2 | 183.6 |
| The health food that FST-8 polypeptide is corresponding | 10.8 | 16.1 | 184.7 |
| The health food that FST-9 polypeptide is corresponding | 10.7 | 15.2 | 189.6 |
| The health food that FST-11 polypeptide is corresponding | 10.6 | 14.6 | 187.6 |
| The health food that FST-13 polypeptide is corresponding | 10.5 | 15.3 | 190.5 |
| The health food that FST-16 polypeptide is corresponding | 10.4 | 14.9 | 187.6 |
| The health food that FST-19 polypeptide is corresponding | 10.6 | 14.8 | 179.5 |
| The health food that FST-20 polypeptide is corresponding | 10.7 | 15.0 | 189.6 |
| The health food that FST-22 polypeptide is corresponding | 10.8 | 15.2 | 191.6 |
| The health food that FST-23 polypeptide is corresponding | 10.4 | 14.9 | 178.6 |
| The health food that FST-25 polypeptide is corresponding | 11.0 | 15.2 | 189.8 |
| The health food that FST-27 polypeptide is corresponding | 10.8 | 14.8 | 187.6 |
| The health food that FST-29 polypeptide is corresponding | 10.7 | 14.7 | 179.3 |
| The health food that FST-32 polypeptide is corresponding | 10.6 | 15.2 | 190.3 |
| The health food that FST-33 polypeptide is corresponding | 10.4 | 15.3 | 191.2 |
| The health food that FST-35 polypeptide is corresponding | 10.5 | 15.3 | 192.1 |
| The health food that FST-37 polypeptide is corresponding | 10.6 | 15.0 | 193.7 |
| The health food that FST-38 polypeptide is corresponding | 10.7 | 14.9 | 187.6 |
| The health food that FST-39 polypeptide is corresponding | 10.6 | 14.8 | 179.6 |
| The health food that FST-42 polypeptide is corresponding | 11.0 | 14.8 | 182.4 |
| The health food that FST-44 polypeptide is corresponding | 11.1 | 14.6 | 183.6 |
| The health food that FST-46 polypeptide is corresponding | 10.7 | 15.0 | 183.2 |
| The health food that FST-48 polypeptide is corresponding | 10.4 | 15.2 | 187.6 |
| The health food that FST-49 polypeptide is corresponding | 10.7 | 15.3 | 179.5 |
| The health food that FST-50 polypeptide is corresponding | 10.9 | 15.6 | 187.6 3 --> |
| The health food that FST-52 polypeptide is corresponding | 10.8 | 14.8 | 186.3 |
| The health food that FST-54 polypeptide is corresponding | 10.4 | 14.7 | 177.4 |
| The health food that FST-55 polypeptide is corresponding | 10.7 | 15.0 | 176.0 |
| The health food that FST-57 polypeptide is corresponding | 10.2 | 15.3 | 179.5 |
| The health food that FST-59 polypeptide is corresponding | 10.3 | 15.6 | 181.6 |
| The health food that FST-62 polypeptide is corresponding | 9.9 | 14.8 | 176.9 |
| The health food that FST-64 polypeptide is corresponding | 10.8 | 14.7 | 190.5 |
| The health food that FST-65 polypeptide is corresponding | 10.7 | 14.8 | 189.3 |
| The health food that FST-66 polypeptide is corresponding | 10.6 | 15.2 | 187.3 |
| The health food that FST-67 polypeptide is corresponding | 10.8 | 15.3 | 189.0 |
| The health food that FST-68 polypeptide is corresponding | 9.8 | 15.4 | 179.9 |
| The health food that FST-69 polypeptide is corresponding | 10.6 | 15.6 | 189.6 |
| The health food that FST-70 polypeptide is corresponding | 10.4 | 14.8 | 187.4 |
| The health food that FST-72 polypeptide is corresponding | 10.7 | 14.7 | 187.6 |
| The health food that FST-74 polypeptide is corresponding | 10.8 | 14.9 | 187.6 |
| The health food that FST-75 polypeptide is corresponding | 10.8 | 15.3 | 188.5 |
| The health food that FST-77 polypeptide is corresponding | 10.6 | 15.2 | 187.6 |
| The health food that FST-79 polypeptide is corresponding | 10.4 | 15.1 | 187.6 |
| The health food that FST-81 polypeptide is corresponding | 10.5 | 14.8 | 189.0 |
| The health food that FST-82 polypeptide is corresponding | 10.7 | 14.7 | 177.4 |
| The health food that FST-83 polypeptide is corresponding | 9.9 | 14.8 | 189.6 |
| The health food that FST-85 polypeptide is corresponding | 10.7 | 14.7 | 199.5 |
| The health food that FST-86 polypeptide is corresponding | 10.3 | 14.3 | 192.5 |
| The health food that FST-88 polypeptide is corresponding | 10.0 | 14.9 | 179.3 |
| The health food that FST-90 polypeptide is corresponding | 10.7 | 15.0 | 188.6 |
| The health food that FST-92 polypeptide is corresponding | 11.0 | 15.1 | 187.5 |
| The health food that FST-93 polypeptide is corresponding | 10.5 | 15.2 | 187.4 |
| The health food that FST-94 polypeptide is corresponding | 11.2 | 14.7 | 190.0 |
| The health food that FST-96 polypeptide is corresponding | 10.5 | 14.8 | 187.5 |
As can be seen from the above results, its effect of effect of the tenth week of the medication of matched group is not highly significant, and this could produce curative effect for more than 15 weeks with the usual medication of methotrexate and be consistent, and the health food of the present invention has better therapeutic effect. And found by the safety monitoring of nearly 10 weeks, the blood to people, liver, kidney etc. does not have side effect. By continuing medication 60 days, the equal pain of patient of 99% disappears, it is possible to action is convenient, it is possible to carries out certain weight loading exercise and keeps not bitterly, has reached therapeutic effect. And eating two patients of methotrexate, although leg pain obtains certain alleviation, but still can not carry out aggravating activities. Can not bear a heavy burden work.
Embodiment 4 randomly selects different polypeptide foods and carries out effect and verify
Example 1: man patient, 29 years old, courier, rheumatic arthritis 3 years, to humidity, cold, excessive physical exertion was sensitive. Use health food corresponding to FST-1 polypeptide, every day 10g, continuous 30 days. Pain symptom disappears, no longer sensitive to external world. Recurrence is not had in a year and a half.
Example 2: man patient, 57 years old, retail stall owner, strong physical work person, to humidity, cold, excessive physical exertion was sensitive. 20 years of past bear rheumatism misery for a long time. Osteoarthritis, mild malformation. Take the health food that FST-39 polypeptide is corresponding, every day 10g, continuous 60 days. Pain symptom disappears, and recovers strong physical work, does not take medicine, also do not have recurrence in 1 year.
Example 3: female patient, 50 years old, food market retailer, to stand for a long time, leg rheumatic arthritis, Symptoms last is more than 10 years. Taking health food corresponding to FST-86 polypeptide 10 grams/day, leg is pain no longer. Drug withdrawal was not recurred in 1 year.
Test result indicate that: all of rheumatoid patient symptom is improved, and does not have recurrence. Therefore, rheumatism therapy is had significant curative effect by the food of the present invention.
Sequence table
< 110 > Li Meng
< 120 > mono-kind is for treating the health food of rheumatism
��160��57
��210��1
��211��19
��212��PRT
< 213 > artificial sequence
��400��FST-1
YSVWQISHLAPQGHIECAR
��210��2
��211��19
��212��PRT
< 213 > artificial sequence
��400��FST-2
KISFQWLWEHHWWTKSRQH
��210��3
��211��18
��212��PRT
< 213 > artificial sequence
��400��FST-4
WNHRSRHQRMCSQNSHQS
��210��4
��211��17
��212��PRT
< 213 > artificial sequence
��400��FST-7
GACQSLNPTSSITDERI
��210��5
��211��18
��212��PRT
< 213 > artificial sequence
��400��FST-8
KGSSYKPRQVPFWWFAEH
��210��6
��211��17
��212��PRT
< 213 > artificial sequence
��400��FST-9
YCVGGSYYYIMSFDRSV
��210��7
��211��16
��212��PRT
< 213 > artificial sequence
��400��FST-11
HRDWKPFWVKEALGHG
��210��8
��211��16
��212��PRT
< 213 > artificial sequence
��400��FST-13
QWRRQRRWTHEDLLQS
��210��9
��211��17
��212��PRT
< 213 > artificial sequence
��400��FST-16
QGVTGYEGCWCNTCACG
��210��10
��211��19
��212��PRT
< 213 > artificial sequence
��400��FST-19
PCSCQASVGWFIHGKPDLK
��210��11
��211��18
��212��PRT
< 213 > artificial sequence
��400��FST-20
RKLIMHKMRKKPQAGDQH
��210��12
��211��16
��212��PRT
< 213 > artificial sequence
��400��FST-22
CWSHIINGSWPWRSFW
��210��13
��211��16
��212��PRT
< 213 > artificial sequence
��400��FST-23
RRRVMKRFVRCWYRSY
��210��14
��211��16
��212��PRT
< 213 > artificial sequence
��400��FST-25
QYDSLIESHWGMHIRY
��210��15
��211��17
��212��PRT
< 213 > artificial sequence
��400��FST-27
LGYSQKQDFRLVMVGWC
��210��16
��211��19
��212��PRT
< 213 > artificial sequence
��400��FST-29
VPHLMGQMRHRLGVPDYVP
��210��17
��211��18
��212��PRT
< 213 > artificial sequence
��400��FST-32
TCWWMQWMRPKCRTMHWQ
��210��18
��211��18
��212��PRT
< 213 > artificial sequence
��400��FST-33
FRSPSRPMALHQQRWATQ
��210��19
��211��17
��212��PRT
< 213 > artificial sequence
��400��FST-35
LKAYRQNCAMQGHMQSV
��210��20
��211��16
��212��PRT
< 213 > artificial sequence
��400��FST-37
WHCFHNKGGEWAVCEF
��210��21
��211��18
��212��PRT
< 213 > artificial sequence
��400��FST-38
TGKGRWSNSRQIFHRFLI
��210��22
��211��17
��212��PRT
< 213 > artificial sequence
��400��FST-39
TWEVSNCGSNWTVYEYH
��210��23
��211��16
��212��PRT
< 213 > artificial sequence
��400��FST-42
RGSMAEFWPWVRHRPH
��210��24
��211��17
��212��PRT
< 213 > artificial sequence
��400��FST-44
KQLCSNQGGFKQQRFGD
��210��25
��211��16
��212��PRT
< 213 > artificial sequence
��400��FST-46
RPGNWRMQMPFPDYYN
��210��26
��211��19
��212��PRT
< 213 > artificial sequence
��400��FST-48
PGPWQHSNDMQQCQPVWYT
��210��27
��211��19
��212��PRT
< 213 > artificial sequence
��400��FST-49
ACWNCWVSLHHRVDIDWKS
��210��28
��211��19
��212��PRT
< 213 > artificial sequence
��400��FST-50
VCPMNDRMSKKMMPDYLTK
��210��29
��211��19
��212��PRT
< 213 > artificial sequence
��400��FST-52
NQVPQQHRHWSLFNPWCTR
��210��30
��211��19
��212��PRT
< 213 > artificial sequence
��400��FST-54
ITSTSEHLSPPMMETDFPI
��210��31
��211��18
��212��PRT
< 213 > artificial sequence
��400��FST-55
WHAMFPHLTHIVVWFDRK
��210��32
��211��18
��212��PRT
< 213 > artificial sequence
��400��FST-57
QTTKSMRRKFQRNTQIVW
��210��33
��211��18
��212��PRT
< 213 > artificial sequence
��400��FST-59
QQTAVQSGTVSHSSVVRR
��210��34
��211��17
��212��PRT
< 213 > artificial sequence
��400��FST-62
PSTIHERMWEWHACQIQ
��210��35
��211��16
��212��PRT
< 213 > artificial sequence
��400��FST-64
SLMHCEHKACQPMGPN
��210��36
��211��17
��212��PRT
< 213 > artificial sequence
��400��FST-65
RVHVWLKAGNGFRTKGG
��210��37
��211��16
��212��PRT
< 213 > artificial sequence
��400��FST-66
YADQKWLHRRPDGYEN
��210��38
��211��19
��212��PRT
< 213 > artificial sequence
��400��FST-67
YSQKWWSQGGVNPRFYLGW
��210��39
��211��19
��212��PRT
< 213 > artificial sequence
��400��FST-68
SPLTEWWEQQAQQQSRFES
��210��40
��211��18
��212��PRT
< 213 > artificial sequence
��400��FST-69
MHEKCRRFQDLQWPMDNW
��210��41
��211��19
��212��PRT
< 213 > artificial sequence
��400��FST-70
NMPPSHVTQWRMWHLYQDY
��210��42
��211��18
��212��PRT
< 213 > artificial sequence
��400��FST-72
MCVDHSETGRSGVGEASY
��210��43
��211��19
��212��PRT
< 213 > artificial sequence
��400��FST-74
FREVQWSNKANNMPQLRFW
��210��44
��211��19
��212��PRT
< 213 > artificial sequence
��400��FST-75
LSRPNASGSIATSHQWHHH
��210��45
��211��18
��212��PRT
< 213 > artificial sequence
��400��FST-77
LQVHFCQIFTDGMHSIDS
��210��46
��211��17
��212��PRT
< 213 > artificial sequence
��400��FST-79
RRSHRDFYYPEQTWHES
��210��47
��211��16
��212��PRT
< 213 > artificial sequence
��400��FST-81
VWPMHVNHHTHPKECF
��210��48
��211��18
��212��PRT
< 213 > artificial sequence
��400��FST-82
IPWNESWVQKNDICIKPE
��210��49
��211��17
��212��PRT
< 213 > artificial sequence
��400��FST-83
ETTGHCSTFCRCTGRML
��210��50
��211��16
��212��PRT
< 213 > artificial sequence
��400��FST-85
RWYQTAHIDHFSWAST
��210��51
��211��18
��212��PRT
< 213 > artificial sequence
��400��FST-86
WQEWALELPKDIATKDAL
��210��52
��211��17
��212��PRT
< 213 > artificial sequence
��400��FST-88
EFGIYKQGWNRYGWFVF
��210��53
��211��16
��212��PRT
< 213 > artificial sequence
��400��FST-90
NYPPIKKFPEQSKSVP
��210��54
��211��17
��212��PRT
< 213 > artificial sequence
��400��FST-92
FGRHKMGTKCRWRTDCG
��210��55
��211��16
��212��PRT
< 213 > artificial sequence
��400��FST-93
YEQECWGGWHWQTRWC
��210��56
��211��17
��212��PRT
< 213 > artificial sequence
��400��FST-94
AYCCTFKDDQMTGENQP
��210��57
��211��16
��212��PRT
< 213 > artificial sequence
��400��FST-96
PWELWNSWVLLYPGAW
Claims (4)
1. a health food, is characterized in that, it is characterised in that be made up of following component: Herba Epimedii 35g, Radix Achyranthis Bidentatae 17g, people 25g, Radix Notoginseng 7g, Flos Carthami 50g, Radix seu Herba Gymnopteris vestitae 10g, yellow mushroom 10g, polypeptide 0.1g, dry Fructus Jujubae 20g, and Fructus Fragariae Ananssae does 20g, sucrose 5g, starch 100g.
2. health food according to claim 1, is characterized in that, peptide sequence is the arbitrary shown sequence of SEQIDNo.1-57.
3. the application in preparing the medicine for treating rheumatism of the health food described in claim 1 or 2.
4. a peptide species, it is characterised in that sequence is the arbitrary shown sequence of SEQIDNo.1-57.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610036925.0A CN105614886A (en) | 2016-01-20 | 2016-01-20 | Health food for treating rheumatism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610036925.0A CN105614886A (en) | 2016-01-20 | 2016-01-20 | Health food for treating rheumatism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105614886A true CN105614886A (en) | 2016-06-01 |
Family
ID=56030582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610036925.0A Pending CN105614886A (en) | 2016-01-20 | 2016-01-20 | Health food for treating rheumatism |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105614886A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1097602A (en) * | 1994-05-25 | 1995-01-25 | 福建省顺昌文华生物工程研究所 | The prescription of Ant Queen Wine and preparation method |
| CN101928745A (en) * | 2010-08-12 | 2010-12-29 | 武汉太极三丰生物科技有限公司 | Preparation method and applications of ant polypeptide |
-
2016
- 2016-01-20 CN CN201610036925.0A patent/CN105614886A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1097602A (en) * | 1994-05-25 | 1995-01-25 | 福建省顺昌文华生物工程研究所 | The prescription of Ant Queen Wine and preparation method |
| CN101928745A (en) * | 2010-08-12 | 2010-12-29 | 武汉太极三丰生物科技有限公司 | Preparation method and applications of ant polypeptide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102613555B (en) | Maca powder and ginseng composition and preparation method thereof | |
| CN102614374A (en) | Chinese medicine tablet with immunoregulation and hypoglycemic effects and preparation method thereof | |
| CN112569305A (en) | Mushroom compound polysaccharide composition for improving immunity and preparation method thereof | |
| US20180369308A1 (en) | Chinese herbal medicine composition having a function of relieving hypothyroidism, preparation method and use thereof | |
| EP1789062A1 (en) | Herb composition for asthma maintenance therapy and manufacturing method thereof | |
| CN100393333C (en) | Chinese medicine composition for treating arthritis and preparing method thereof | |
| CN105617354A (en) | Medicine for treating rheumatism and rheumatoid | |
| WO2023125797A1 (en) | Traditional chinese medicine composition and preparation method and application thereof | |
| CN104055935A (en) | Traditional Chinese medicine composition for improving immunity in synergetic mode | |
| CN104436145B (en) | It is a kind of to prevent and/or treatment allergic rhinitis and the pharmaceutical composition of allergic asthma | |
| CN103960663A (en) | Health care food for enhancing immunologic function and preparation method of food | |
| CN108186920B (en) | Pharmaceutical composition with auxiliary blood fat reducing effect and preparation method thereof | |
| CN105687480A (en) | Immunoregulatory traditional Chinese medicine composition and preparation | |
| CN105614886A (en) | Health food for treating rheumatism | |
| CN113633682B (en) | Cream for treating herpes zoster and preparation method thereof | |
| JPH0761953B2 (en) | Manufacturing method of immunity strengthening and constitution improving agent | |
| CN1803163A (en) | Chinese medicine for treating AIDS | |
| CN102579947A (en) | Chinese medicinal composition and preparation method thereof | |
| CN101829213B (en) | Medicine composition for treating asthma and preparation method thereof | |
| CN106540044A (en) | It is a kind of to treat pharmaceutical composition of rheumatoid arthritis and preparation method thereof | |
| Kusnul et al. | Consumption of herbal teas decrease health problems (fatigue, cough and throat problems, skin problems, and stomatitis) | |
| CN105311065A (en) | Application of aleuritopteris argentea extract in preparation of medicines for treating cardiovascular and cerebrovascular diseases | |
| CN104352850A (en) | Extraction method of bamboo shavings extract | |
| CN1323628A (en) | Kidney-invigorating and male sexual function improving traditional Chinese medicine prepn. | |
| CN105535056A (en) | Traditional Chinese medicine preparation for treating viral meningitis and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160601 |